“For patients with severe and pre-critical illnesses, we found that plasma therapy does work!” Professor Xinxin Zhang of the Clinical Virus Research Laboratory of Ruijin Hospital said, “In fact, plasma therapy is not something new, the use of plasma therapy for diphtheria patients has won the Nobel Prize, the treatment of SARS, H1N1 have been shown to be effective, and the new Coronavirus Pneumonia is a new and serious disease, and there are a lot of serious patients, humans do not have much knowledge of this disease, so we must refer to the So we have to refer to the past experience of treatment. When the Wuhan Virus Laboratory test found that the plasma of the recovered patients did have neutralizing antibodies with high potency, we immediately began preliminary clinical trials in Jinyintan, the First Hospital of Jiangxia District, and the Combined Traditional Chinese and Western Medicine Hospital of Jiangxia District.” Seeing the patients white lung improvement ecstatic Zhou Min, director of the Department of Respiratory Medicine, Ruijin Hospital, the initial 10 patients to do the plasma therapy of the rehabilitators, of which one was discharged, five improved, four stabilized, and found that most of the patients did have significant improvement in clinical symptoms after treatment, due to the new coronary pneumonia is characterized by alveolar epithelial cell damage, on the CT will be presented with a ground-glass-like changes, this change if alleviated also indicates that the inflammatory storm has abated. “When we saw that the patient’s lung shadow (white lung) showed significant absorption on CT, we were really ecstatic!” Zhou Min said, “Medically and ethically, we need to use this method as soon as possible to save more patients, especially the critically ill ones.” Prof. Qu Jieming, chairman of the Respiratory Disease Branch of the Chinese Medical Association, said that plasma from recovered patients who meet the discharge criteria of 7-14 days or less is more effective for treatment. In addition, we believe that the more severe the viral replication, the better the effect of plasmapheresis, for the heavy viral load can sometimes block the inflammatory storm, of course, the optimal timing of plasmapheresis is still to be observed in a larger population. Currently, the timing of plasmapheresis is recommended for patients with severe or pre-critical illnesses. We do not recommend plasmapheresis for patients with mild to moderate illnesses, and plasmapheresis is less effective in patients with advanced critical illnesses when the inflammatory factor storm is too intense and is combined with ARDS or multiorgan failure. At this time, the use of inflammatory factor inhibitors such as tolizumab should be synergistic, the results of this study have been published by Zhou Guangbiao, Chen Saijuan academician by the Higher Education Publishing House, the Chinese Academy of Engineering, Shanghai Jiaotong University co-sponsored the journal “Frontiers of Medicine,” and has been proposed, the recovery plasma containing specific anti-neocoronavirus neutralizing antibody and inhibit the cytokine storm of tolizumab form a synergistic combination of therapeutic, included in the The next version of the National Pilot Program for Neocoronavirus Pneumonia. Plasma therapy is effective, but safety must be ensured The effectiveness and safety of a treatment must be considered in terms of both effectiveness and safety. Is plasma therapy safe? China Biotechnology Corporation (China Biological) Yang Xiaoming researcher pointed out that first of all must standardize the physical examination of the rehabilitants to ensure that their blood does not contain hepatitis and other viruses, in addition, plasma collection should be subjected to rigorous virus inactivation. As of February 22, rehabilitation plasma treatment of 10 cases of severe patients, including 1 case of discharge, 5 cases of improvement, 4 cases of stability; treatment of 8 cases of critical illness, including 4 cases of improvement, 3 cases of stability, 1 case of death. In the past two days, 18 cases of new treatment admissions of severe diseases. Accordingly, the total number of cases treated by the rehabilitation plasma therapy has reached 36, and no patient has had any adverse reaction so far. In the future, China Biotech will further research and manufacture specific immunoglobulin. “We call for more recovered people to participate in plasma donation, and also recommend the use of plasma therapy at the clinical frontline for patients with severe and pre-critical illnesses. If our cured patients are grateful to the medical staff for saving their lives, let’s ask them to actively donate plasma as well to save more lives.” Academician Ning Guang, president of Ruijin Hospital, initiated the initiative. Content source: Xinmin Evening News